Outcomes of Patients With Newly Diagnosed AML and Hyperleukocytosis

Fadi G. Haddad; Koji Sasaki; Jayastu Senapati; Lianchun Xiao; Grace S. Park; Tareq Abuasab; Sangeetha Venugopal; Daniel Rivera; Alexandre Bazinet; Rodrick Babakhanlou; Kunhwa Kim; Faustine Ong; Sai Prasad Desikan; Naveen Pemmaraju; Sanam Loghavi; Gautam Borthakur; Courtney DiNardo; Hussein A. Abbas; Nicholas J. Short; Naval Daver; Elias Jabbour; Guillermo Garcia‐Manero; Farhad Ravandi; Hagop M. Kantarjian; Tapan M. Kadia

doi:10.1200/op.24.00027

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

AML presenting with hyperleukocytosis is associated with poor outcomes. We aim to understand the factors associated with early mortality and overall survival (OS) to help guide management and improve early mortality.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Haddad et al. (2024) studied this question.

synapsesocial.com/papers/68e60139b6db643587595141 https://doi.org/10.1200/op.24.00027

View at Publisher

Ask AI

Bookmark

Share

Outcomes of Patients With Newly Diagnosed AML and Hyperleukocytosis

Ask about this paper

Abstract

Discussion

Cite This Study

Outcomes of Patients With Newly Diagnosed AML and Hyperleukocytosis

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading